Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis

Xiaoyan Chang,* Chenghao Wang,* Linyou Zhang Department of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China*These authors contributed equally to this workCorrespondence: Linyou Zhang, Department of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China, Tel +8615145106696, Email [email protected]: This study seeks to identify research trends and hotspots concerning tyrosine kinase inhibitors (TKIs) for the treatment of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) through a comprehensive bibliometric analysis.Methods: Publications on TKIs and EGFR-mutated NSCLC from 2006 to 2024 were analyzed using VOSviewer, CiteSpace, and R-bibliometrix to visualize collaboration, keyword co-occurrences, and research trends.Results: A total of 962 articles were analyzed, authored by 7,458 researchers from 5,401 institutions across 208 countries. Wu Yi-Long was identified as the most prolific author, contributing 30 publications. AstraZeneca emerged as the industrial leader with 103 articles, while the New England Journal of Medicine was recognized as the primary journal with the highest total link strength. Keyword co-occurrence analysis revealed significant research topics including “gefitinib”, “chemotherapy”, “open label”, and “erlotinib.” Moreover, keyword burst analysis indicated notable periods of increased research focus on topics such as “osimertinib” and “liquid biopsy”, suggesting emerging trends and current hotspots in the treatment of EGFR-mutated NSCLC.Conclusion: This analysis highlights research trends on TKIs for EGFR-mutated NSCLC, emphasizing the importance of targeted therapies like gefitinib and osimertinib for future research and clinical practice enhancement.Keywords: tyrosine kinase inhibitors, non-small cell lung cancer, bibliometrics, CiteSpace, VOSviewer

Publication Details

Journal
SHILAP Revista de lepidopterología
Published
2025-03-01
Primary Topic
Magnetic confinement fusion research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis

SHILAP Revista de lepidopterología
Magnetic confinement fusion research
article

Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis

article en

Abstract

Xiaoyan Chang,* Chenghao Wang,* Linyou Zhang Department of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China*These authors contributed equally to this workCorrespondence: Linyou Zhang, Department of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China, Tel +8615145106696, Email [email protected]: This study seeks to identify research trends and hotspots concerning tyrosine kinase inhibitors (TKIs) for the treatment of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) through a comprehensive bibliometric analysis.Methods: Publications on TKIs and EGFR-mutated NSCLC from 2006 to 2024 were analyzed using VOSviewer, CiteSpace, and R-bibliometrix to visualize collaboration, keyword co-occurrences, and research trends.Results: A total of 962 articles were analyzed, authored by 7,458 researchers from 5,401 institutions across 208 countries. Wu Yi-Long was identified as the most prolific author, contributing 30 publications. AstraZeneca emerged as the industrial leader with 103 articles, while the New England Journal of Medicine was recognized as the primary journal with the highest total link strength. Keyword co-occurrence analysis revealed significant research topics including “gefitinib”, “chemotherapy”, “open label”, and “erlotinib.” Moreover, keyword burst analysis indicated notable periods of increased research focus on topics such as “osimertinib” and “liquid biopsy”, suggesting emerging trends and current hotspots in the treatment of EGFR-mutated NSCLC.Conclusion: This analysis highlights research trends on TKIs for EGFR-mutated NSCLC, emphasizing the importance of targeted therapies like gefitinib and osimertinib for future research and clinical practice enhancement.Keywords: tyrosine kinase inhibitors, non-small cell lung cancer, bibliometrics, CiteSpace, VOSviewer

SHILAP Revista de lepidopterología
Partnerships for the goals
Openalex Percentile: Top 43%
Magnetic confinement fusion research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Research Trends of Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer: A Bibliometric Analysis · SHILAP Revista de lepidopterología (2025) | TGRS Research Map | TGRS